

TRANSPLANT AREAS OF INTEREST

June 2025



Investigator Sponsored Studies : ANTI-THYMOCYTE GLOBULIN (RABBIT)

Sanofi has made the decision to no longer support new requests for investigator sponsored studies (ISS) aiming to study the potential benefits of anti-thymocyte globulin (ATG) on the management of autoimmune type 1 diabetes.

This decision comes after long consideration on how Sanofi can maximize its positive impact and overall value in autoimmune type 1 diabetes research. In line with our overarching company guidance, we believe that focusing on the development of first-in-class or best-in-class treatments is how we can deliver the most value to the T1D community.



Internal



AREAS OF INTEREST - THYMOGLOBULIN

Report areas of Interest for potential Investigator Sponsored Studies: interesting to support if proposed by external investigator/sponsor. This list will be posted on [Sanofi portal](#).

Areas of Interest	Gap/Unmet need addressed
Thymoglobulin in heart transplantation (US)	Thymoglobulin induction in heart transplantation: potential for label harmonization across geographies (US market only)



AREAS OF INTEREST - BELUMOSUDIL - cGVHD



Report areas of Interest for potential Investigator Sponsored Studies: interesting to support if proposed by external investigator/sponsor. This list will be posted on [Sanofi portal](#).

Areas of Interest	Gap/Unmet need addressed
Combination Therapies in cGVHD using novel agent (1 st and/or 2 nd /3 rd line)	• Novel agents with MoA demonstrating activity in cGVHD and non-overlapping toxicities and addressing unmet needs
Defining local / regional patterns in treating cGVHD and RWE sequencing of belumosudil	• Jak1/2 inhibitors • CSF-1R (IV and oral) • SYC-1
Preclinical studies on ROCK-2 inhibition, dependence and escape	• Translation preclinical studies that further characterize ROCK2 inhibition impact on inflammation and fibrosis • Preclinical rationale for ROCK-2 inhibition combination approaches to overcome potential escape mechanisms
Prophylactic therapy in GVHD (acute, chronic)	• Improved upon PTCY backbone for GVHD prophylaxis - in higher unmet need populations (elderly, haplo HSCT)
1 st Line Therapy combining belumosudil with other standard treatments "steroids sparing" in cGVHD	Identify novel belumosudil "steroid sparing" combinations that improve ORR - Preference goes towards already established MoAs in cGVHD



AREAS OF INTEREST – BELUMOSUDIL - CLAD

Report areas of Interest for potential Investigator Sponsored Studies: interesting to support if proposed by external investigator/sponsor. This list will be posted on [Sanofi portal](#).

Areas of Interest	Gap/Unmet need addressed
Rezurock in lung transplantation	• ROCK2 pathway and Rezurock in CLAD, • Treatment patterns, SoC and alternative treatment options • CLAD prevalence and incidence
Single lung transplantation	• CLAD in single lung transplantation • ROCK2 pathway, treatment opportunities • Long term outcomes
Transplantation of heart-lung complex	• Heart lung complex and CLAD • CNI sparing with ROCK2 pathway • Pathology of transplanted lung